Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.

Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P.

Expert Opin Investig Drugs. 2007 Oct;16(10):1601-13. Review.

PMID:
17922624
2.

The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.

Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E.

Arthritis Res Ther. 2006;8(1):R33. Epub 2006 Jan 13.

3.

Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.

Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Fishman P.

Arthritis Res Ther. 2006;8(6):R169.

4.

Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.

Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P.

J Rheumatol. 2005 Mar;32(3):469-76.

PMID:
15742438
5.

The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease.

Ochaion A, Bar-Yehuda S, Cohen S, Barer F, Patoka R, Amital H, Reitblat T, Reitblat A, Ophir J, Konfino I, Chowers Y, Ben-Horin S, Fishman P.

Cell Immunol. 2009;258(2):115-22. doi: 10.1016/j.cellimm.2009.03.020. Epub 2009 May 7.

PMID:
19426966
6.
7.

The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P.

Biochem Pharmacol. 2008 Aug 15;76(4):482-94. doi: 10.1016/j.bcp.2008.05.032. Epub 2008 Jun 17.

8.

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P.

J Rheumatol. 2008 Jan;35(1):41-8. Epub 2007 Nov 15.

PMID:
18050382
9.

Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.

Bar-Yehuda S, Rath-Wolfson L, Del Valle L, Ochaion A, Cohen S, Patoka R, Zozulya G, Barer F, Atar E, PiƱa-Oviedo S, Perez-Liz G, Castel D, Fishman P.

Arthritis Rheum. 2009 Oct;60(10):3061-71. doi: 10.1002/art.24817.

10.

A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.

Vincenzi F, Padovan M, Targa M, Corciulo C, Giacuzzo S, Merighi S, Gessi S, Govoni M, Borea PA, Varani K.

PLoS One. 2013;8(1):e54195. doi: 10.1371/journal.pone.0054195. Epub 2013 Jan 11.

11.

Pharmacology and therapeutic applications of A3 receptor subtype.

Fishman P, Bar-Yehuda S.

Curr Top Med Chem. 2003;3(4):463-9. Review.

PMID:
12570762
12.

ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis.

Guzman J, Yu JG, Suntres Z, Bozarov A, Cooke H, Javed N, Auer H, Palatini J, Hassanain HH, Cardounel AJ, Javed A, Grants I, Wunderlich JE, Christofi FL.

Inflamm Bowel Dis. 2006 Aug;12(8):766-89.

PMID:
16917233
13.

The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.

Fishman P, Cohen S.

Clin Rheumatol. 2016 Sep;35(9):2359-62. doi: 10.1007/s10067-016-3202-4. Epub 2016 Feb 17. Review.

PMID:
26886128
14.

Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation.

Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L, Pinto A.

Cancer Biol Ther. 2008 Feb;7(2):278-84. Epub 2007 Nov 14.

PMID:
18059189
15.

The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways.

Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P.

Int J Oncol. 2008 Aug;33(2):287-95.

PMID:
18636149
16.

IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.

Rath-Wolfson L, Bar-Yehuda S, Madi L, Ochaion A, Cohen S, Zabutti A, Fishman P.

Clin Exp Rheumatol. 2006 Jul-Aug;24(4):400-6.

PMID:
16956430
17.

NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer.

Calzado MA, Bacher S, Schmitz ML.

Curr Med Chem. 2007;14(3):367-76. Review.

PMID:
17305539
18.

A3 adenosine receptor: pharmacology and role in disease.

Borea PA, Gessi S, Bar-Yehuda S, Fishman P.

Handb Exp Pharmacol. 2009;(193):297-327. doi: 10.1007/978-3-540-89615-9_10. Review.

PMID:
19639286
19.

MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.

Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, Xu D.

J Pharmacol Exp Ther. 2008 May;325(2):425-34. doi: 10.1124/jpet.107.134510. Epub 2008 Feb 20.

20.

Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.

Morello S, Sorrentino R, Porta A, Forte G, Popolo A, Petrella A, Pinto A.

J Cell Physiol. 2009 Nov;221(2):378-86. doi: 10.1002/jcp.21863.

PMID:
19562684

Supplemental Content

Support Center